The Efficacy and Safety of Arotinolol Combined With a Different Calcium Channel Blocker in the Treatment of Chinese Patients with Essential Hypertension: A One- Year Follow-Up Study

The Efficacy and Safety of Arotinolol Combined With a Different Calcium Channel Blocker in the Treatment of Chinese Patients with Essential Hypertension

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004132

Enrollment

Unknown

Registered

2014-01-10

Start date

2014-01-08

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertensive

Interventions

amlodipine:amlodipine+arotinolol

felodipine group:felodipine plus arotinolol

Eligibility

Sex/Gender

All

Age

64 Years to 78 Years

Inclusion criteria

Inclusion criteria: Patients with over ten years clinical features of essential hypertension were studied from year 2003 to 2012 at our hospital. The hypertension diagnosis was according to AHA hypertensive guideline.

Exclusion criteria

Exclusion criteria: malignant and severe hypertension, secondary hypertension, II-III degree AVB, sinus bradycardia(HR<50bpm), NYHA heart function 4th degree, allergic asthma, obstructive pulmonary disease, severe liver or renal diseases.

Design outcomes

Primary

Measure	Time frame
blood pressure;	—

Countries

China

Contacts

Public ContactFang Hong

de_61@163.com+86 021 66111529

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026